A novel targeted T-cell modulator, efalizumab, for plaque psoriasis
Article Abstract:
The drug Raptiva from Genentech may be effective in treating severe psoriasis, according to a study of 597 patients. The drug was given as a subcutaneous injection once a week for up to six months. Between 22% and 28% of the patients had a 75% or greater improvement in symptoms, depending on the dose. Raptiva prevents the activation of T cells that cause psoriasis.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial
Article Abstract:
The drug Raptiva may benefit many patients with moderate to severe psoriasis, according to a study of 556 patients. About half of the patients who took Raptiva experienced an improvement in their symptoms, compared to less than 20% of those who took a placebo, or inactive substance. Raptiva blocks specific T cells that cause psoriasis.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
Immunologic targets in psoriasis
Article Abstract:
The drugs Raptiva and Enbrel represent a new way of treating a skin disease called psoriasis. Both drugs affect the immune system because psoriasis is a type of autoimmune disease in which the immune system attacks the body. They may be effective in treating patients with severe psoriasis, according to two studies published in 2003.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Influence of indomethacin on extracellular calcium homeostasis. Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial
- Abstracts: Doctor-backed bill seeks to help uninsured. Naturopaths are eligible for licensure in California
- Abstracts: A special message on late-term abortion from the AMA board chair. 30 years after oRoe v. Wadeo, doctors reflect on its impact
- Abstracts: Reduced profit margins common for groups in 2002. Battle of the beds. Deck the office for a seasonal treat, but keep it tasteful
- Abstracts: Molecular cytogenetics: an essential component of modern prenatal diagnosis. Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome